Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Dec 15;5(1):98.
doi: 10.1186/s40478-017-0500-2.

Absence of MGMT promoter methylation in diffuse midline glioma, H3 K27M-mutant

Rouzbeh Banan  1 , Arne Christians  1 , Stephan Bartels  2 , Ulrich Lehmann  2 , Christian Hartmann  3
Affiliations

Absence of MGMT promoter methylation in diffuse midline glioma, H3 K27M-mutant

Rouzbeh Banan et al. Acta Neuropathol Commun. .
No abstract available

Keywords: Diffuse midline glioma H3 K27M-mutant; H3F3A; HIST1H3B; MGMT.

PubMed Disclaimer

Conflict of interest statement

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Genomic structure of the MGMT promoter. The CpG island covers the major part of the promoter region including Exon 1. The two CpG sites analyzed by the Illumina 450 K array (highlighted in red) are not associated with the DHMR as the common target region in the routinely performed assays using MS-PCR and Pyrosequencing. Our newly designed pyrosequencing assay (purple box) targets the distal section of the promoter overlapping DHMR and includes 4/6 CpG sites that highly correlate with MGMT mRNA expression
See this image and copyright information in PMC

References

    1. Aldape K, Zadeh G, Mansouri S, Reifenberger G, von Deimling A. Glioblastoma: pathology, molecular mechanisms and markers. Acta Neuropathol. 2015;129:829–848. doi: 10.1007/s00401-015-1432-1. - DOI - PubMed
    1. Babu R, Kranz PG, Agarwal V, McLendon RE, Thomas S, Friedman AH, Bigner DD, Adamson C. Malignant brainstem gliomas in adults: clinicopathological characteristics and prognostic factors. J Neuro-Oncol. 2014;119:177–185. doi: 10.1007/s11060-014-1471-9. - DOI - PMC - PubMed
    1. Babu R, Kranz PG, Karikari IO, Friedman AH, Adamson C. Clinical characteristics and treatment of malignant brainstem gliomas in elderly patients. J Clin Neurosci. 2013;20:1382–1386. doi: 10.1016/j.jocn.2012.12.011. - DOI - PubMed
    1. Bady P, Sciuscio D, Diserens AC, Bloch J, van den Bent MJ, Marosi C, Dietrich PY, Weller M, Mariani L, Heppner FL, et al. MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. Acta Neuropathol. 2012;124:547–560. doi: 10.1007/s00401-012-1016-2. - DOI - PMC - PubMed
    1. Everhard S, Tost J, El Abdalaoui H, Criniere E, Busato F, Marie Y, Gut IG, Sanson M, Mokhtari K, Laigle-Donadey F, et al. Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas. Neuro-Oncology. 2009;11:348–356. doi: 10.1215/15228517-2009-001. - DOI - PMC - PubMed